Millennium Management Llc discloses stake in PBYI / Puma Biotechnology Inc
Puma Biotechnology reports interim SUMMIT results for neratinib | Drug Discovery News
Puma Biotechnology, Inc. (PBYI) Company Information - Simply Wall St
Former Puma Biotechnology exec is accused of making $1.2 million from insider trading - Los Angeles Times
Puma Biotechnology
Puma Biotechnology (PBYI) Stock Climbs On Orphan Drug Designation | Alpha Stock News
Why Puma Biotechnology Is Soaring Today | The Motley Fool
PUMA BIOTECHNOLOGY, INC. FORM 8-K/A - Shareholder.com
Puma Biotechnology, Inc. 2018 Q3 - Results - Earnings Call Slides (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology Announces Exclusive License Agreement with Takeda for the Development and Commercialization of Alisertib, an Investigational Aurora Kinase A Inhibitor | Business Wire
Puma Biotechnology
Puma Biotechnology
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | citybiz
Exhibitor Puma Biotechnology 11-6 - Scripps CME Connection
Federal Jury Awards Puma Biotechnology Investors Damages in Securities Class-Action Verdict - Los Angeles Business Journal
Puma Biotechnology falls more than 20%
Puma Biotechnology: Still Bullish At These Prices (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology (PBYI) Presents At Barclays Global Healthcare Virtual Conference (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | Business Wire
Puma Biotechnology
Puma Biotechnology Announces Exclusive License Agreement with Takeda for the Development and Commercialization of Alisertib, an Investigational Aurora Kinase A Inhibitor | Business Wire
Puma Biotechnology
Puma Biotech agrees to pay investors $54.2 mln in fraud case | Reuters
